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Highlights
We discuss the history of regulation of nicotine for vaping in Australia
Current Australian laws provide two options for regulating nicotine for vaping 
No products have been approved for sale under option 1 (prescription medicine)
We propose using option 2 (dangerous poison) to trial a nicotine licence scheme
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A Licence to vape: Is it time to trial a nicotine licensing scheme to allow Australian adults 
controlled access to personal vaporiser devices and refill solutions containing nicotine?
Abstract
Australia has some of the most restrictive laws concerning use of nicotine in e-cigarettes. The 
only current legal option for Australians to legally possess and use nicotine for vaping is with 
a medical prescription and domestic supply is limited to compounding pharmacies who 
prepare medicines for specific patients. An alternative regulatory option that could be 
implemented under current drugs and poisons regulations is a ‘nicotine licensing’ scheme 
utilising current provisions for ‘dangerous poisons’. This commentary discusses how such a 
scheme could be used to trial access to nicotine solutions for vaping outside of a ‘medicines 
framework’ in Australia.
Keywords: nicotine; electronic cigarettes; nicotine licensing;
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Background
E-cigarettes (also known as personal vaporisers or electronic nicotine delivery 
systems) have been mass-marketed as a ‘cleaner’ form of recreational nicotine than tobacco 
cigarettes since around 2006 in the USA, UK and Europe. The use of these devices has grown 
substantially in recent years, suggesting they have wide appeal to smokers (Yong et al., 
2014). These devices work by heating a mixture (or ‘juice’) of propylene glycol and/or 
vegetable glycerine, nicotine and flavourings to produce an aerosol that is inhaled by the user. 
Unflavoured and nicotine-free solutions are also sold. 
There is a wide variety of e-cigarettes available that include: single use disposable 
devices that resemble conventional cigarettes in appearance; rechargeable devices that use 
replaceable pre-filled cartridges; refillable tank style (or ‘ego’) devices; and bespoke devices 
produced by and for collectors. The refillable device styles allow greater user control, 
including the option to ‘mix your own’ juice, and in some cases, alter the heating 
temperature. Using an e-cigarette is known as ‘vaping’ and regular users often refer to 
themselves as ‘vapers’.
A very substantial public health gain could be achieved if a substantial proportion of 
smokers switch to e-cigarettes, because the health risks of regular use of these products are 
likely to be much lower than those of cigarette smoking (Abrams, 2014; Hajek, Etter, 
Benowitz, Eissenberg, & McRobbie, 2014; Royal College of Physicians, 2007). Critics argue, 
on the other hand, that some of the hard fought for gains that have been achieved from 
tobacco control policies could be lost if increased use of e-cigarettes  led to an increased 
uptake of smoking among non-smokers, or discouraged quitting among smokers if most e-
cigarette users continued to smoke cigarettes while using e-cigarettes (dual use) instead of 
quitting smoking (Chapman, 2013, 2014).
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The population health impact of e-cigarettes will depend on patterns of e-cigarette 
uptake, the way in which these devices are used by smokers and whether their use increases 
or decreases smoking.  Evidence from the UK suggests that widespread access to e-cigarettes 
has not had a detrimental effect on smoking prevalence which has declined in population 
surveys as e-cigarette use has increased, and e-cigarette use is very rare among non-smokers 
(Dockrell, Morrison, Bauld, & McNeill, 2013).  An observational study of UK smokers that 
had made a quit attempt without formal cessation assistance in the past 12 months indicated 
that those who used an e-cigarette were more likely to be abstinent from smoking at follow-
up than those who either used no aid or approved nicotine replacement therapies (NRT) 
purchased over the counter (Brown et al., 2014). While the emerging evidence indicates that 
quitting success rates are still relatively modest with e-cigarettes, they do appear to increase 
the success rate of quit attempts and may be superior to approved over the counter NRT 
products (McRobbie, Bullen, Hartmann-Boyce, & Hajek, 2014; Brown et al., 2014; Bullen et 
al., 2013).
The risks associated with short-term e-cigarette use appear to be very low and similar 
to approved NRT products (McRobbie et al., 2014; Bullen et al., 2013; Caponnetto et al., 
2013). There is only limited information on the risks of long-term e-cigarette use (Hajek et 
al., 2014). It is also unclear what percentage of e-cigarette users will continue to use these 
products indefinitely and how many will use e-cigarettes as an interim step towards nicotine 
abstinence.
The Legal Status of E-cigarettes in Australia
The legal status of e-cigarettes in Australia is complicated (Douglas, Hall, & Gartner, 
2015). Australia’s regulatory framework for medicines and poisons classifies substances into 
nine schedules. Nicotine falls under different schedules, depending upon its intended use. 
Nicotine in tobacco intended for smoking is exempt from scheduling and so are therapeutic 
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cessation aids for oromucosal or transdermal use (e.g. gum, lozenges, mouth spray, patches 
etc). All other nicotine preparations for human therapeutic use are Schedule 4 (prescription 
only medicines), such as nicotine nasal spray. Nicotine in preparations of 3% nicotine or less 
packed and sold for the treatment of animals is in Schedule 6; for all other non-therapeutic 
applications, Schedule 7 (dangerous poison) applies. All nicotine preparations that are 
claimed to have a therapeutic application (e.g. smoking cessation aid), must gain approval 
from the Therapeutic Goods Administration (TGA) and be listed on the Australian Register 
of Therapeutic Goods (ARTG) before being supplied within Australia. 
In June 2008, The National Drugs and Poisons Scheduling Committee (NDPSC) 
considered the issue of e-cigarettes containing nicotine (National Drugs and Poisons 
Scheduling Committee [NDPSC], 2008). The Victorian jurisdictional member proposed that 
the Schedule 4 entry for nicotine be amended to cover internal human use (non tobacco), not 
solely for therapeutic use, to make electronic cigarettes available as ‘Prescription Only’ 
products. This option was rejected by the committee, which concluded “that the current 
scheduling of nicotine remained appropriate”. At the time, Schedule 2 (over the counter 
Pharmacy sales) would apply to e-cigarettes that claimed to assist in smoking cessation. 
Schedule 7 (Dangerous Poison) would apply if this claim was not made.
In 2011, the NDPSC again considered e-cigarettes and the Nicorette inhaler/inhalator 
(NDPSC, 2011). The committee “noted that the current Schedule 2 entry for nicotine for 
inhalation was intended to capture oromucosal inhalators and not nicotine vaporiser products 
(e.g. e-cigarettes). Members clarified that e-cigarettes should be captured by Schedule 4 when 
for human therapeutic use or by Schedule 7 if for non-therapeutic use.” The Schedule 2 entry 
for nicotine for inhalation was deleted and the Nicorette inhaler was renamed “inhalator” and 
included in the exemption from scheduling for smoking cessation aids containing nicotine 
“for oromucosal or transdermal use”, thereby allowing them to be sold over the counter in 
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general retail outlets. All other nicotine preparations for human therapeutic use, including e-
cigarettes that gain TGA approval, would now be included under Schedule 4 (Prescription 
only medicines). Nicotine for non-therapeutic use remains under Schedule 7 (dangerous 
poisons). Since no e-cigarettes are currently listed on the ARTG, schedule 7 applies to e-
cigarettes and refill solutions if they contain nicotine, and if they do not make therapeutic 
claims. 
In all Australian states it is an offence to manufacture, sell or supply nicotine as a 
schedule 7 poison, without a licence or specific authorisation. This means that e-cigarettes 
containing nicotine and nicotine refill solutions cannot be sold or supplied lawfully 
commercially in any Australian state for non-therapeutic purposes as no licences or 
authorities have been issued. There are several reported incidents where individuals have 
been charged with the illegal supply of liquid nicotine for use in e-cigarettes in Queensland 
(AAP, 2014; Cook, 2014). In all Australian states it is also either illegal to possess or illegal 
to use nicotine as a Schedule 7 poison (i.e. when not considered a therapeutic good) without 
an approval, permit or authority (Douglas et al., 2015). This presents a regulatory dilemma 
for state health departments. Prosecu ing individual e-cigarette users who are using these 
products to remain abstinent from smoking is arguably not in the public interest. A good case 
can also be made for not expending scarce departmental resources on investigating and 
prosecuting individuals for possession or use, if there is no evidence of a serious threat to 
public health from this possession or use. 
The current situation places e-cigarette users in the position of breaking the law for an 
activity that may be reducing their health risks. While some argue that access to unapproved 
e-cigarettes is unnecessary because approved nicotine products are available (Duff & 
Corderoy, 2014), it should be noted that none of these therapeutic products are approved for 
long-term substitution (which some e-cigarette users argue they need to maintain abstinence 
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from smoking). Many e-cigarette users report that they have failed to quit smoking using 
these products and that they have only been able to become and remain abstinent by using e-
cigarettes (Fraser, Weir, Keane, & Gartner, 2015). Smokers and e-cigarette users can 
reasonably question the rationality of regulations that make possession and use of e-cigarettes 
by adults illegal while allowing the retail sale of nicotine in the most harmful form (tobacco 
cigarettes) (Hall, Gartner, & Forlini, 2015).   
The sale of nicotine-free e-cigarettes and ‘juice’ are not specifically banned under 
legislation. In all states it is not illegal to possess a e-cigarette without nicotine. However, 
tobacco control legislation in some states bans the sale of any non-tobacco products that “are 
designed to resemble” a tobacco product (Douglas et al., 2015). The first prosecution of a e-
cigarette vendor in Western Australia was initially unsuccessful, but on appeal a conviction 
was recorded. The vendor has since appealed this conviction. From the beginning of 2015, 
Queensland tobacco control legislation now applies the same restrictions to sale and use of e-
cigarettes and refill solutions as apply to tobacco cigarettes. e-cigarettes and refill solutions 
containing nicotine are still banned in Queensland under drugs and poisons legislation. While 
this new legislation imposes substantial restrictions on the sale and use of e-cigarettes, it does 
explicitly make it legal to sell and use e-cigarettes in Queensland. Similar controls are also 
being considered in other states and territories.
Despite the current legal barriers, e-cigarettes and nicotine juice are widely available 
over the internet or ‘under the counter’ (Duff, 2013). The use of e-cigarettes has increased 
rapidly in recent years in Australia, from 2% of smokers and recent quitters reporting having 
ever used a vaporiser in 2010 to nearly 20% in 2013 (Yong et al., 2014).  Of the 8.9% of 
Australian smokers who reported current use of a e-cigarette in 2013, 43% reported using 
nicotine in their e-cigarette and a further 21% did not know if their vaporiser contained 
nicotine or not. Levels of use are much higher in countries which regulate e-cigarettes as 
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general consumer products rather than as medicines (e.g. USA and UK). Current e-cigarette 
use among smokers and recent quitters (<1 year) was 18% in USA and 19% in UK in 2013.  
If the overseas e-cigarette market continues to grow, these products could become even more 
widespread within Australia via international travel and internet purchases.
Current legal options for accessing nicotine solutions for vaping in Australia
As a therapeutic good for smoking cessation
One legal way for Australians to access nicotine solutions for e-cigarettes is via the 
TGA personal importation scheme for unapproved medicines. This is only available if the 
person uses the nicotine for therapeutic use (e.g. as a smoking cessation aid or to manage the 
symptoms of withdrawal of tobacco) (Therapeutic Goods Administration [TGA], 2013a). 
This scheme allows Australians to import up to a 3 month supply at a time of nicotine as an 
unapproved medicine without any approval required by the TGA, if the person holds a 
prescription from an Australian-registered medical practitioner for it. Compounding 
pharmacists can also legally compound a nicotine solution for supply to an individual patient 
on medical prescription. However, both of these options are probably too onerous and 
unattractive for most smokers unacquainted with vaping, especially socioeconomically 
disadvantaged smokers among whom ‘hardcore’ smokers are now concentrated in Australia 
(Clare, Bradford, Courtney, Martire, & Mattick, 2014). These are the smokers who are most 
likely to substantially benefit from using long term nicotine substitution so it is important to 
find another way to enable heavily addicted smokers or smokers unmotivated to quit to be 
able to access e-cigarettes for harm reduction purposes.
In principle, medical practitioners could prescribe an e-cigarette for therapeutic 
purposes, but there are no e-cigarettes  listed for medical use on the ARTG. The main barrier 
to e-cigarettes gaining TGA registration for smoking cessation is that obtaining registration is 
an expensive and lengthy process. Furthermore, while ARTG listing would ensure e-
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cigarettes were of a consistent high quality, any substantive changes to e-cigarette devices 
would require new applications to the TGA to deal with changes in a rapidly evolving 
technology. This could deter further innovation and improvements in the product design 
(Bates & Stimson, 2013). Some commentators have also argued that regulating e-cigarettes as 
medicines works in favour of the tobacco industry, which now sells e-cigarettes. The tobacco 
industry have the financial resources to obtain medicines approval for their products while 
smaller independent e-cigarette manufacturers may not. 
An optimistic view of the entry of tobacco companies into the e-cigarette market is 
that these products provide the tobacco industry with an ‘exit strategy’. However, many 
public health professionals are suspicious of their motives and intentions because e-cigarette 
companies owned by tobacco companies may have less incentive to promote their products as 
complete replacements for cigarettes than companies that only manufacture e-cigarettes 
(Freeman 2014). Many of the Australian public health professionals who are concerned about 
tobacco industry involvement in the e-cigarette industry support regulation of e-cigarettes as 
medicines1 (Carrick, 2014; Cancer Council Australia & National Heart Foundation of 
Australia, 2014). Paradoxically, restricting regulation of e-cigarettes to a medicines 
framework may work to the advantage of the tobacco industry by reducing the diversity of e-
cigarette products on the market and also competition from e-cigarettes not owned by tobacco 
companies. 
Promoting e-cigarettes as medicines is also likely to reduce their attractiveness to 
smokers. A survey of Australian e-cigarette users found that: 93% opposed access only via 
doctor’s prescription (Schedule 4); 85% opposed access as a pharmacist only medicine 
                                                            
1 “If any manufacturer producer wants to sell e-cigarettes as a cessation aid, all they need to 
do is take the product to the Therapeutic Goods Administration with good evidence, and then 
see if they can get it approved. Whether it's a small businessman, this fellow Van Heerden in 
Perth, or whether it's the big tobacco companies that are buying into e-cigarettes big time…. 
That's the way to go.” (Mike Daube, “E-Cigarettes: Should We Inhale”. The Law Report, 
ABC Radio National. 10 June 2014)
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(Schedule 3); and 81% opposed access as a pharmacy only medicine (Schedule 2) (Fraser et 
al., 2014). The time and financial cost of obtaining a medical prescription for purchasing PVs 
is a further disincentive to use, especially in light of recent proposals from the 
Commonwealth government to force GPs to charge patients a  co-payment for bulk-billed 
visits (Duckett, 2014).
Policy options for regulating e-cigarettes and nicotine
There are a number of policy options for regulating e-cigarettes and non-therapeutic 
nicotine available to the Australian government. The first option is to maintain the status quo, 
as described above. This current policy can be criticised on ethical grounds because it 
effectively denies access to a less harmful alternative to smoking while allowing widespread 
sale of a more harmful product (cigarettes) (Hall, Gartner & Forlini, 2015). It also does not 
address the growing illicit market in nicotine in Australia and the risk of childhood 
poisonings, which could be reduced through appropriate labelling and child-resistant 
packaging. 
Amend therapeutic goods regulation
Australia’s therapeutic goods regulations are not well suited for regulating products 
that are arguably non-therapeutic. An example of an approach to regulate recreational 
psychoactive substances to minimise harm and improve their safety and quality is New 
Zealand’s Psychoactive Substances Act 2013, which requires all products to be approved by 
the Psychoactive Substances Regulatory Authority (Newberry, Wodak, Sellman & Robinson, 
2014). The Act also requires all importers, researchers, manufacturers, wholesalers, and 
retailers to be licenced. The regulations that provide for product approval applications and 
licensing applications for importing, research and manufacturing to be processed, came into 
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force in November 2014. Hence, there has been insufficient time to judge the success of this 
approach.
Consumer protection legislation
Existing consumer protection laws cover general aspects of product safety, including 
electrical safety. Specific standards for e-cigarettes and vaping solutions could be developed 
and adopted as an Australian Standard, similar to the proposed British Standards Institute 
standard (BSI, 2014). This could address many concerns related to the safety of PVs and 
liquids, including specifying which additives (e.g. diacetyl) should not be used in vaping 
solutions and setting performance standards for maximum emissions limits. However, 
development of an Australian Standard would not address the current legal barriers to sale, 
possession and use of nicotine-containing e-cigarettes in Australia.
Amend or reinterpret poisons regulations
One option to widen public access to nicotine for vaping would be to reschedule 
nicotine from Schedule 7 to Schedule 5. This would address packaging and labelling 
concerns, but would not place any restrictions on where or to whom nicotine could be sold 
without additional legislation.  Rescheduling nicotine would require all Australian states and 
territories to agree to this change, which could present a substantial challenge. Alternatively, 
state health departments could consider allowing adults to access nicotine for vaping under 
the existing licensing/approval arrangements for schedule 7 poisons, a framework that has 
some resemblance to a licensing scheme proposed by Chapman and Liberman (2005). This is 
the option that we discuss in more detail because it is feasible to trial under current legislation 
in most Australian states and may be more likely to be supported by the Australian tobacco 
control and public health community than less restrictive options, given the conservative 
approach favoured by many leading Australian public health advocacy groups (Cancer 
Council Australia & National Heart Foundation of Australia, 2014). We do not propose this 
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as the optimal regulatory approach, but rather a pragmatic option available under current 
regulations that deserves discussion and consideration.
A nicotine licensing scheme for non-therapeutic nicotine use
In 2005, Chapman and Liberman proposed a ‘smoker licensing scheme’ that would 
restrict sales of tobacco to licensed smokers (Chapman & Liberman, 2005). In 2012, 
Chapman elaborated on the merits of this scheme and argued that a smoker’s licence would 
be similar to how a doctor’s prescription in provides a temporary licence to purchase and use 
Schedule 4 medicines (Chapman, 2012). In a published debate on how e-cigarettes should be 
regulated, Chapman proposed the application of a user licence to these nicotine products, 
arguing that this “would balance the right to use e-cigarettes with all the constraints and 
disincentives that are now, and should be further, applied to cigarettes” (Chapman, 2013). 
Using the analogy of a medical prescription as a temporary licence, a nicotine licence for 
buying and selling non-TGA approved e-cigarettes would restrict access to e-cigarettes in 
much the same way as access to prescription-only medicines is restricted. The critical 
difference would be that the government would not provide “some tacit support for 
(medically supervised) use of an untested and unproven product” (National Drugs and 
Poisons Scheduling Committee, 2008).
The main elements of a smoker licensing scheme outlined by Chapman and Liberman 
(2005) include:
 Requirement of a knowledge test of the risks of smoking
 Presentation of a photo ID smart card on each occasion of purchase 
 Recording all purchases were recorded against a licence
 Purchasing limits in the smart card to prevent large scale purchasing for  on-
selling to unlicensed smokers 
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 Provision of financial incentives to encourage licensed smokers who quit to 
surrender their cards to reduce the chance of relapsing (because they would 
need to apply for a new licence to purchase cigarettes if they did so)
Implementing a smoker’s licensing scheme would be a major undertaking and would 
radically change the way that tobacco is currently sold in Australia. However, applying a 
similar scheme to nicotine-containing e-cigarettes would be more straightforward since there 
is no current legal market for these products for non-therapeutic use and there are many fewer 
users of e-cigarettes than cigarette smokers. While a survey of Australian vapers found that a 
majority opposed a licensing scheme (60%), there were twice as many participants ‘open’ to 
the idea than was the case for over the counter pharmacy only sales (Fraser et al., 2015). This 
suggests a licensing option may potentially be more acceptable to current e-cigarette users 
than other options that use a medical framework (Schedules 2-4), as long as the regulations 
were not too burdensome. 
The potential benefits of trialling a nicotine licensing scheme are that it provides 
regulated access to adults who want to use these products in a way that: targets adult smokers 
and deters young non-smokers; provides an alternative to the black market of inappropriately 
labelled and packed nicotine products; and provides critical data to assess uptake of nicotine-
containing e-cigarettes by smokers and non-smokers, their impact on smoking and the extent 
to which users engage in dual use (i.e. continue to smoke cigarettes when able to do so). 
A License under the Schedule 7 poison regulations
The Australian regulations for Schedule 7 ‘dangerous poisons’ provide an existing 
framework for a ‘nicotine licence’ for sellers and buyers of nicotine-containing e-cigarettes 
for non-therapeutic human use. The Schedule 7 listing of nicotine has been justified by the 
NDPSC because it prohibits the use of nicotine intended for non-therapeutic use in order to 
protect public health and ensures that “individuals cannot gain access” (NDPSC, 2008). 
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However, state drugs and poisons legislation also allow persons to have controlled access to 
Schedule 7 poisons via a ‘licence’ and/or ‘approval’ process in certain circumstances. These 
provisions could, in principle, be adapted to ‘license’ or ‘approve’ nicotine sellers and users 
for the purposes of a trialling sales of non-therapeutic nicotine for vaping in Australia. 
Proposed Nicotine Licensing/approval scheme
Wholesalers and retailers could apply for a poison seller’s licence/approval that was 
restricted to the sale of nicotine products up to a maximum strength concentration. Users 
could apply for an approval for the purchase, possession and use of nicotine products. If 
desirable, or necessary under current legislation, ‘fit and proper’ or ‘suitable’ person 
requirements for retailer licence and/or user approvals could include:
 No history of previous conviction for selling tobacco or alcohol to underage 
persons
 No history of previous conviction for selling illicit drugs
 Demonstration of adequate knowledge of safe storage and handling practices 
for nicotine 
 Demonstration of adequate knowledge of their legal requirements as a licensed 
nicotine retailer/approved nicotine user
Other possible inclusions not currently required under current legislation:
 Users could be required to acknowledge that they understand that the products 
purchased under the approval may not meet the standards of therapeutic goods  
 Limits could be set on the amount of nicotine and maximum % concentration 
approved users are allowed to possess at any time to avoid commercial 
quantities being purchased and sold on black market
 If an application fee for user approvals is charged, this could be fully refunded 
if surrendered within 3 months (or at any longer time) to reduce barriers for 
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smokers wanting to try the products without committing to long-term use or 
using them to quit.
 Approval and photo id could be presented to licensed retailers when making 
purchases. 
Current legislative requirements include maintaining records of all Schedule 7 poisons 
sales for a minimum period of time (e.g. 2 years in Queensland). Retailers could also be 
required to periodically provide aggregated data on sales to facilitate public health research 
on the nicotine market. Approved purchasers could also be periodically surveyed about their 
nicotine use, cigarette consumption and any adverse effects to monitor impact of nicotine use 
on smoking and health. 
Advantages and disadvantages
A major advantage of the licensing approach to nicotine for use in e-cigarettes is that 
it could be implemented immediately under current legislation covering Schedule 7 
chemicals in some states. This would provide a legal way for smokers to access these 
products until TGA approved products become available or other regulatory options requiring 
a change of laws are approved. The scheme could be easily wound up if it was no longer 
necessary. Schedule 7 regulations would require these products to be sold in child-resistant 
packaging and to be accurately labelled in terms of nicotine content and labelled with safe 
storage and handling instructions (e.g. ‘keep out of the reach of children’). If the scheme is 
successful (i.e. most Australian vapers switch to purchasing their nicotine products via the 
scheme), this could reduce some of the potential hazards of the proliferation of black-market 
products that are packaged in non-child resistant packages and are inappropriately labelled 
(no ingredients list, inaccurate nicotine content, no safe handling advice). This approach 
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could address the reported increase in child poisonings related to nicotine products that have 
been inappropriately packed and labelled (Hagan, 2014).
The current legislative requirements for recording and retention of Schedule 7 poison 
sales data would allow diversion of legally purchased nicotine products to the illicit market 
by approved purchasers and licensed retailers to be investigated (most likely on a complaints-
driven basis). Measures to proactively reduce diversion by enforcing limits on total quantities 
that could be sold and monitoring transactions along the supply chain (from 
manufacturer/wholesaler to retailer to consumer) would require a more sophisticated system,
such as is mandated for pseudoephedrine sales in Queensland (Berbatis, Sunderland, & 
Dhaliwal, 2009). This involves a secure website which records in real-time pseudoephedrine 
sales against purchasers’ details. Individuals wishing to purchase preparations containing 
pseudoephedrine present their photo id to the pharmacist who then enters the purchaser into 
the database (Devaney, Ferris & Mazerolle, 2014). Such a monitoring system would involve 
a significant cost burden. Project STOP (pseudoephedrine real-time monitoring system) is 
funded by the Pharmacy Guild and cost $500,000 to setup and $650,000 per year to maintain 
(The Pharmacy Guild of Australia, 2013). Another example of a seller/purchaser licensing 
model is Uruguay’s proposed cannabis licensing scheme, which will allow licenced growers 
and sellers to produce and s ll cannabis within specified limits (quantity and THC content). 
Purchasers will be required to register with a database run by the Ministry of Health and will 
be limited to purchasing 40 grams/month through pharmacies and the user registry aims to 
prevent the bundling of repeat purchase of small amounts to avoid detection (Pardo, 2014). 
The government will need to determine if the risk of diversion of nicotine for vaping to the 
black market warrants this level of monitoring.
The major advantage of utilising existing legislation it that it is not clear what level of 
regulation of these products is most likely to benefit public health. A trial of a nicotine 
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licensing scheme would allow valuable data to be collected that would assist in determining 
what form of regulation is appropriate for nicotine-containing e-cigarettes. If there was a need 
for a longer term scheme, then legislative changes could make it more appropriate for e-
cigarettess. For example, labelling requirements could be amended to provide specific advice 
for use of e-cigarettes, or if monitoring sales of nicotine at the user end was found to be 
unnecessary, recording of sales against approval numbers could be removed. There is also 
considerable scope within this option to implement a range of approaches from a relatively 
‘light touch’ basic version (e.g. just licensing retailers) up to a more tightly controlled version 
closer to Chapman’s proposed “smoker’s licence”.
The main disadvantage of this approach is the substantial administrative burden it 
imposes on government, retailers and users. Some e-cigarette users may be opposed to 
records being kept of their nicotine purchases or being required to apply for an approval to 
possess and use nicotine when no such requirement is placed on tobacco. Some labelling 
requirements for Schedule 7 poisons (e.g. the warning “Dangerous Poison”)(TGA, 2013b)
may be inappropriate for e-cigarettes given that similar levels of nicotine can be found in 
currently unscheduled nicotine products (e.g. Nicorette inhalator, Nicorette Quickmist 
Mouthspray). Some states place restrictions on the purposes for which Schedule 7 user 
permits/approvals can be issued. One of the allowed purposes is ‘research’, hence it is 
possible that issuing approvals as part of a research trial could be facilitated. Only one state 
(Victoria) explicitly prohibits Schedule 7 poison sellers licences to be issued for retailing 
nicotine for non-therapeutic human use.
Current tobacco control legislation in Western Australia, New South Wales, and 
South Australia could present a barrier to sale of the e-cigarette devices (Douglas et al., 
2015). The final outcome of the Van Heerden case will be critical in determining whether the 
sale of all e-cigarette devices is prohibited by this legislation in Western Australia, or only 
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those that physically resemble cigarettes. If necessary, this legislation could be amended to 
permit sale by licensed sellers to approved adult purchasers. Otherwise, the licensing scheme 
may be limited to refill solutions only. Users in these states would need to source the devices 
from other states or from overseas (e.g. via the internet). This restriction would probably 
reduce the number of smokers who would switch to e-cigarettes. The proposed licensing 
scheme is more paternalistic and restrictive than current controls on smoked tobacco but 
much less so than the current de facto ban on the sale and use of nicotine in e-cigarettes (Hall 
et al., 2015). Current users may (justifiably) feel that the extra controls on sale and purchase 
are an unfair imposition when such controls are not placed on tobacco purchases. However, 
there is an even larger regulatory gap between the current approach to non-therapeutic 
nicotine use (prohibition) and what current users may see is an acceptable level of regulation 
(e.g. only an 18+ age restriction on sales). Where current laws allow for approvals to be 
issued to obtain, possess and use Schedule 7 poisons, it is arguably more ethical to allow 
adults who can demonstrate they are able to store and use nicotine safely to obtain an 
approval under these conditions than to deny them the option of applying for and obtaining 
an approval. 
Some may raise objections that introducing licensing for nicotine could be a potential 
‘Trojan horse’ for licensing smokers (Chapman, 2013). Regardless of whether a licensing 
scheme for smokers is desirable or not, we don’t believe this is a sufficient reason not to 
discuss this option as a viable one for nicotine-containing e-cigarettes, given the limited 
options that are available under current Australian laws. This option is a compromise that 
may facilitate legal access to nicotine for vaping in a way that allows the collection of 
valuable data that can help to decide what sort of regulatory scheme Australia should 
ultimately adopt toward these products. Running a research trial of such a scheme for a 
limited time period (e.g. 2 years) would allow these data to be collected and set a date for 
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review and evaluation of how useful and appropriate this regulatory option was compared to 
the other current alternatives such as medicines approval or a de facto ban.
Conclusion
Current Australian regulations prohibit the possession and use of nicotine for non-
therapeutic purposes without an approval or other authority. The proposed nicotine licensing 
scheme could potentially provide Australian adult smokers with a way to legally access 
nicotine for use in e-cigarettes to reduce their health risk under current poisons regulations 
without the barriers of medicines regulation. It could also address the risk of child poisonings 
from inappropriately packed and labelled nicotine solutions. This scheme may serve as an 
interim measure until TGA approved e-cigarettes are available or other regulatory options are 
adopted. Alternatively, if there are benefits in maintaining the licensing scheme, it would be 
possible to make legislative amendments to make it more appropriate for e-cigarette products.
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